ProtAffin AG starts Phase 1 study for lead product PA401 in inflammatory lung disease
Advertisement
ProtAffin AG announced that it has started dosing healthy volunteers in a Phase 1 clinical study in the UK with its novel investigational anti-inflammatory product, PA401.
PA401 is a modified form of the human chemokine IL-8. Human IL-8 (CXCL8) is a chemokine produced by macrophages and other cells and its primary function is the attraction of neutrophils to sites of acute and chronic inflammation. PA401 acts as a potent, targeted anti-inflammatory protein preventing the infiltration of neutrophils which is a hallmark of many respiratory diseases including chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF).